Clinical Trials Browser

Phase 1/2 × recombinant interferon alpha 2b-like protein × 90 days × Clear all

NCT04380545 2026-03-06

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular